Critical care management of acute ischemic stroke

Current Opinion in Critical Care

Volumn 10, Issue 2, 2004, Pages 110-115

  Andrews, Peter J D ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Acute ischaemic stroke; Critical care; Randomized trials; Thrombolysis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALCOHOL; ALTEPLASE; ANCROD; ANTITHROMBOCYTIC AGENT; CAFFEINE; CAFFEINOL; FIBRINOGEN; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; PARACETAMOL; ROVELIZUMAB; SARUPLASE; STREPTOKINASE; TIROFIBAN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UROKINASE; VASCULAR CELL ADHESION MOLECULE 1;

AIRWAY; ARTIFICIAL VENTILATION; BODY TEMPERATURE; BRAIN DECOMPRESSION; BRAIN EDEMA; BREATHING; CEREBRAL ARTERY DISEASE; CEREBROVASCULAR ACCIDENT; CIRCULATION; CLINICAL TRIAL; CRANIECTOMY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EUROPEAN UNION; FEVER; FIBRINOLYTIC THERAPY; GLUCOSE BLOOD LEVEL; HUMAN; IMMUNOMODULATION; INTENSIVE CARE; PNEUMONIA; REVIEW; ULTRASOUND THERAPY; UNITED STATES;

ACUTE DISEASE; BLOOD GLUCOSE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CRITICAL CARE; FEVER; FIBRINOGEN; HUMANS; PNEUMONIA; RESPIRATION, ARTIFICIAL; THROMBOLYTIC THERAPY;

EID: 1942423135     PISSN: 10705295     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075198-200404000-00006     Document Type: Review

References (35)

1. Liu M, Counsell C, Wardlaw J: Fibrinogen depleting agents for acute ischaemic stroke [update in Cochrane Database Syst Rev 2003(3):CD000091; PMID: 12917882]. ]. Cochrane Database Syst Rev 2000,CD000091.
2. Liu M, Wardlaw J: Thrombolysis (different doses, routes of administration and agents) for acute ischaemic stroke. Cochrane Database Syst Rev 2000, CD000514.
3. Wardlaw JM, del Zoppo G, Yamaguchi T: Thrombolysis for acute ischaemic stroke [update in Cochrane Database Syst Rev 2003(3):CD000213; PMID: 12917889]. Cochrane Database Syst Rev 2000,CD000213. This is a useful summary of the current quality evidence for this intervention. To date, there are only data on a relatively small number of patient interventions. This has limited our ability to make informed judgments about timing of the intervention and the likely benefit and risk.
4. Sherman DG: Ancrod. Curr Med Res Opin 2002, 18(suppl 2):s48-s52.
5. Glas-Greenwalt P: Safe and successful clinical use of the defibrinogenating agent ancrod. Blood 1992, 80:1626-1628.
6. Sherman DG: Antithrombotic and hypofibrinogenetic therapy in acute ischemic stroke: what is the next step? Cerebrovasc Dis 2004, 17(suppl 1):138-143.
7. Hossmann V, Heiss WD, Bewermeyer H, et al.: Controlled trial of ancrod in ischemic stroke. Arch Neurol 1983, 40:803-808.
8. Pollak VE, Glas-Greenwalt P, Olinger CP, et al.: Ancrod causes rapid thrombolysis in patients with acute stroke. Am J Med Sci 1990, 299:319-325.
9. Dempfle CE, Alesci S, Kucher K, et al.: Plasminogen activation without changes in tPA and PAI-1 in response to subcutaneous administration of ancrod. Thromb Res 2001, 104:433-438.
10. Liu M, Counsell C, Zhao XL, et al.: Fibrinogen depleting agents for acute ischaemic stroke [update of Cochrane Database Syst Rev 2000(2):CD000091; PMID: 10796295]. Cochrane Database Syst Rev 2003, CD000091. Updated search of the Cochrane Stroke Group Trials Register (to May 2003), EMBASE (1980-October 2001), China Biological Medicine Database (CBM-disc 1981-December 2002), Chinese Stroke Trials Register (1996-December 2002), and Index of Scientific and Technical Proceedings. Fibrinogen-depleting agents moderately reduced the proportion of patients who were dead or disabled at the end of follow-up.
11. Samsa GP, Matchar DB, Williams GR, et al.: Cost-effectiveness of ancrod treatment of acute ischaemic stroke: results from the Stroke Treatment with Ancrod Trial (STAT). J Eval Clin Pract 2002, 8:61-70.
12. Sherman DG: Antithrombotic therapy in the acute phase: new approaches. Cerebrovasc Dis 2001, 11 (suppl 1):49-54.
13. Bogousslavsky J, Paciaroni M, Gallai V: Glycoprotein (GP) IIb/IIIa inhibitors for acute stroke treatment. Clin Exp Hypertens 2002, 24:603-610.
14. Lee DH, Jo KD, Kim HG, et al.: Local intraarterial urokinase thrombolysis of acute ischemic stroke with or without intravenous abciximab: a pilot study. J Vasc Interv Radiol 2002, 13:769-774.
15. Eckert B, Koch C, Thomalla G, et al.: Acute basilar artery occlusion treated with combined intravenous Abciximab and intra-arterial tissue plasminogen activator: report of 3 cases. Stroke 2002, 33:1424-1427.
16. Hofmann R, Kerschner K, Steinwender C, et al.: Abciximab bolus injection does not reduce cerebral ischemic complications of elective carotid artery stenting: a randomized study. Stroke 2002, 33:725-727.
17. Morris DCS: Treatment of acute stroke with recombinant tissue plasminogen activator and abciximab. Acad Emerg Med 2003, 10:1396-1399. This is a pilot study of combined therapy. This sort of approach is appealing from the mechanistic point of view and may reduce risk and increase benefit.
18. Seitz RJ, Hamzavi M, Junghans U, et al.: Thrombolysis with recombinant tissue plasminogen activator and tirofiban in stroke: preliminary observations. Stroke 2003, 34:1932-1935.
19. Heo JH, Lee KY, Kim SH, et al.: Immediate reocclusion following a successful thrombolysis in acute stroke: a pilot study. Neurology 2003, 60:1684-1687.
20. Piriyawat P, Labiche LA, Burgin WS, et al.: Pilot dose-escalation study of caffeine plus ethanol (caffeinol) in acute ischemic stroke. Stroke 2003, 34:1242-1245. This is an interesting and well-conducted phase I trial. Target plasma levels were achieved easily for both agents. Positive results from an outcome trial are needed, but I believe that this combination is already popular with my northern European aging population (personal observation).
21. Behrens S, Spengos K, Daffertshofer M, et al.: Potential use of therapeutic ultrasound in ischemic stroke treatment. Echocardiography 2001, 18:259-263.
22. Chamorro A, Catillo J, Davalos A: Early administration of high-dose IV unfractioned heparin blunts sVCAM-a and improves functional outcome more effective than 300mg oral aspirin in acute ischaemic stroke. 26th International Stroke Conference. Stroke 2000, 32:373-a.
23. Becker KJ: Targeting the central nervous system inflammatory response in ischaemic stroke. Curr Opin Neurology 2001, 14:349-354.
24. Weir CJ, Murray GD, Dyker AG, et al.: Is hyperglycaemia an independent predictor of poor outcome after acute stroke? Results of a long-term follow up study. BMJ 1997, 314:1303-1306.
25. Brown DL, Johnston KC, Wagner DP, et al.: Predicting major neurological improvement with intravenous recombinant tissue plasminogen activator treatment of stroke. Stroke 2004, 35:147-150. Further post hoc analysis of the National Institute of Neurological Disorders and Stroke rt-PA study database. This is an attempt to find factors that might predict good response to thrombolysis.
26. Diez-Tejedor E, Fuentes B: Acute care in stroke: do stroke units make the difference? Cerebrovasc Dis 2001, 11(suppl 1):31-39.
27. Mesotten D, Van den BG: Clinical potential of insulin therapy in critically ill patients. Drugs 2003, 63:625-636.
28. Els T, Klisch J, Orszagh M, et al.: Hyperglycemia in patients with focal cerebral ischemia after intravenous thrombolysis: influence on clinical outcome and infarct size. Cerebrovasc Dis 2002, 13:89-94.
29. Kilpatrick MM, Lowry DW, Firlik AD, et al.: Hyperthermia in the neurosurgical intensive care unit. Neurosurgery 2000, 47:850-855.
30. Dippel DW, van Breda EJ, van der Worp HB, et al.: PISA-Investigators: effeet of paracetamol (acetaminophen) and ibuprofen on body temperature in acute ischemic stroke PISA, a phase II double-blind, randomized, placebo-controlled trial. BMC Cardiovascular Disorders 2003, 3:2. [ISRCTN98608690] A simple to institute intervention might have a major health economic benefit.
31. Knoll T, Wimmer ML, Gumpinger F, et al.: The low normothermia concept-maintaining a core body temperature between 36 and 37 degrees C in acute stroke unit patients. J Neurosurg Anesthesiol 2002, 14:304-308.
32. Georgiadis D, Schwarz S, Aschoff A, et al.: Hemicraniectomy and moderate hypothermia in patients with severe ischemic stroke. Stroke 2002, 33:1584-1588.
33. Hilker R, Poetter C, Findeisen N, et al.: Nosocomial pneumonia after acute stroke: implications for neurological intensive care medicine. Stroke 2003, 34:975-981.
34. Georgiadis D, Schwarz S, Baumgartner RW, et al.: Influence of positive end-expiratory pressure on intracranial pressure and cerebral perfusion pressure in patients with acute stroke. Stroke 2001, 32:2088-2092.
35. Georgiadis D, Schwarz S, Kollmar R, et al.: Influence of inspiration expiration ratio on intracranial and cerebral perfusion pressure in acute stroke patients. Intensive Care Med 2002, 28:1089-1093.